The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.
Bertrand Tombal
Consultant or Advisory Role - Ferring
Honoraria - Ferring
Other Remuneration - Ferring
Jan-Erik Damber
Consultant or Advisory Role - Ferring
Anders Malmberg
Employment or Leadership Position - Ferring
Bo-Eric Persson
Employment or Leadership Position - Ferring
Laurence Klotz
Honoraria - Ferring
Research Funding - Ferring
Peter Iversen
Consultant or Advisory Role - Ferring
Honoraria - Ferring
Other Remuneration - Ferring